192 related articles for article (PubMed ID: 30483892)
1. The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.
Mielke J; Innerbichler F; Schiestl M; Ballarini NM; Jones B
AAPS J; 2018 Nov; 21(1):7. PubMed ID: 30483892
[TBL] [Abstract][Full Text] [Related]
2. Statistical Approaches to Assess Biosimilarity from Analytical Data.
Burdick R; Coffey T; Gutka H; Gratzl G; Conlon HD; Huang CT; Boyne M; Kuehne H
AAPS J; 2017 Jan; 19(1):4-14. PubMed ID: 27709452
[TBL] [Abstract][Full Text] [Related]
3. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
Kwon O; Joung J; Park Y; Kim CW; Hong SH
Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
[TBL] [Abstract][Full Text] [Related]
4. Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars.
Vandekerckhove K; Seidl A; Gutka H; Kumar M; Gratzl G; Keire D; Coffey T; Kuehne H
AAPS J; 2018 May; 20(4):68. PubMed ID: 29748754
[TBL] [Abstract][Full Text] [Related]
5. Pragmatic rules for comparability of biological medicinal products.
van der Plas RM; Hoefnagel MHN; Hillege HL; Roes KCB
Biologicals; 2020 Jan; 63():97-100. PubMed ID: 31836276
[TBL] [Abstract][Full Text] [Related]
6. On the establishment of equivalence acceptance criterion in analytical similarity assessment.
Wang T; Chow SC
J Biopharm Stat; 2017; 27(2):206-212. PubMed ID: 28051920
[TBL] [Abstract][Full Text] [Related]
7. Development of statistical methods for analytical similarity assessment.
Tsong Y; Dong X; Shen M
J Biopharm Stat; 2017; 27(2):197-205. PubMed ID: 27977326
[TBL] [Abstract][Full Text] [Related]
8. Analytical Similarity Assessment in Biosimilar Studies.
Chow SC; Song F; Bai H
AAPS J; 2016 May; 18(3):670-7. PubMed ID: 26873509
[TBL] [Abstract][Full Text] [Related]
9. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
10. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
Yang H; Novick S; Burdick RK
PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
12. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
[TBL] [Abstract][Full Text] [Related]
13. Differentiating biosimilarity and comparability in biotherapeutics.
Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
[TBL] [Abstract][Full Text] [Related]
14. Key considerations in the preclinical development of biosimilars.
Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
[TBL] [Abstract][Full Text] [Related]
15. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.
Alsamil AM; Giezen TJ; Egberts TC; Leufkens HG; Vulto AG; van der Plas MR; Gardarsdottir H
Eur J Pharm Sci; 2020 Nov; 154():105501. PubMed ID: 32739253
[TBL] [Abstract][Full Text] [Related]
16. The process defines the product: what really matters in biosimilar design and production?
Vulto AG; Jaquez OA
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv14-iv29. PubMed ID: 28903544
[TBL] [Abstract][Full Text] [Related]
17. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
19. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
[TBL] [Abstract][Full Text] [Related]
20. Sample size requirement in analytical studies for similarity assessment.
Chow SC; Song F; Bai H
J Biopharm Stat; 2017; 27(2):233-238. PubMed ID: 27935446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
